Skip to main content
main-content

Tip

Swipe om te navigeren naar een ander artikel

01-12-2011 | Review | Uitgave 1/2011 Open Access

Journal of Foot and Ankle Research 1/2011

Safety and efficacy of tinea pedis and onychomycosis treatment in people with diabetes: a systematic review

Tijdschrift:
Journal of Foot and Ankle Research > Uitgave 1/2011
Auteurs:
Lisa Matricciani, Kerwin Talbot, Sara Jones
Belangrijke opmerkingen

Electronic supplementary material

The online version of this article (doi:10.​1186/​1757-1146-4-26) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests. This study received no funding

Authors' contributions

LM carried out the systematic review and study appraisal and drafted the manuscript. KT carried out the systematic review and study appraisal. SJ assisted to locate studies of relevance for the study and assisted in the appraisal of included studies. All authors read and approved the final manuscript.

Abstract

Background

Effective treatment of tinea pedis and onychomycosis is crucial for patients with diabetes as these infections may lead to foot ulcers and secondary bacterial infections resulting in eventual lower limb amputation. Although numerous studies have assessed the effectiveness of antifungal drug and treatment regimens, most exclude patients with diabetes and examine otherwise healthy individuals. While these studies are useful, results cannot necessarily be extrapolated to patients with diabetes. The purpose of this study was to therefore identify the best evidence-based treatment interventions for tinea pedis or onychomycosis in people with diabetes.

Methods

The question for this systemic review was: 'what evidence is there for the safety and/or efficacy of all treatment interventions for adults with tinea pedis and/or onychomycosis in people with diabetes'? A systematic literature search of four electronic databases (Scopus, EbscoHost, Ovid, Web of Science) was undertaken (6/1/11). The primary outcome measure for safety was self-reported adverse events likely to be drug-related, while the primary outcome measures assessed for 'efficacy' were mycological, clinical and complete cure.

Results

The systematic review identified six studies that examined the safety and/or efficacy of treatment interventions for onychomycosis in people with diabetes. No studies were identified that examined treatment for tinea pedis. Of the studies identified, two were randomised controlled trials (RCTs) and four were case series. Based on the best available evidence identified, it can be suggested that oral terbinafine is as safe and effective as oral itraconazole therapy for the treatment of onychomycosis in people with diabetes. However, efficacy results were found to be poor.

Conclusions

This review indicates that there is good evidence (Level II) to suggest oral terbinafine is as safe and effective as itraconazole therapy for the treatment of onychomycosis in people with diabetes. Further research is needed to establish the evidence for other treatment modalities and treatment for tinea pedis for people with diabetes. Future efforts are needed to improve the efficacy of treatment intervention.

Onze productaanbevelingen

BSL Podotherapeut Totaal

Binnen de bundel kunt u gebruik maken van boeken, tijdschriften, e-learnings, web-tv's en uitlegvideo's. BSL Podotherapeut Totaal is overal toegankelijk; via uw PC, tablet of smartphone.

Extra materiaal
Authors’ original file for figure 1
13047_2011_351_MOESM1_ESM.pdf
Authors’ original file for figure 2
13047_2011_351_MOESM2_ESM.jpeg
Authors’ original file for figure 4
13047_2011_351_MOESM3_ESM.doc
Literatuur
Over dit artikel

Andere artikelen Uitgave 1/2011

Journal of Foot and Ankle Research 1/2011Naar de uitgave